Amicus Therapeutics Inc. | Mid-cap | Healthcare
$7.61
0.13%
| Amicus Therapeutics Stock Comparison:
Amicus Therapeutics vs VertexAmicus Therapeutics vs RegeneronAmicus Therapeutics vs BridgeBio PharmaAmicus Therapeutics vs MadrigalAmicus Therapeutics vs HalozymeAmicus Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 125.2M
Gross Profit 113.6M 90.66%
Operating Income -8.0M -6.35%
Net Income -21.7M -17.31%
EPS (Diluted) $-0.07

Balance Sheet Metrics

Total Assets 789.8M
Total Liabilities 596.3M
Shareholders Equity 193.6M
Debt to Equity 3.08

Cash Flow Metrics

Operating Cash Flow 16.7M
Free Cash Flow 7.5M

Revenue & Profitability Trend

Amicus Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i528.3M399.4M329.2M305.5M260.9M
Cost of Goods Sold i52.9M37.3M38.6M34.5M31.0M
Gross Profit i475.4M362.0M290.6M271.0M229.8M
Gross Margin % i90.0%90.7%88.3%88.7%88.1%
Operating Expenses
Research & Development i109.4M152.4M276.7M272.0M308.4M
Selling, General & Administrative i323.4M275.3M213.0M192.7M156.4M
Other Operating Expenses i-----
Total Operating Expenses i432.7M427.7M489.7M464.8M464.8M
Operating Income i34.1M-73.5M-204.4M-199.9M-243.9M
Operating Margin % i6.4%-18.4%-62.1%-65.4%-93.5%
Non-Operating Items
Interest Income i5.4M7.1M3.0M509.0K3.2M
Interest Expense i49.6M50.1M37.1M32.5M22.4M
Other Non-Operating Income-18.6M-33.5M-3.5M-9.7M-11.2M
Pre-tax Income i-28.8M-150.1M-242.0M-241.6M-274.3M
Income Tax i27.4M1.5M-5.5M8.9M2.6M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-56.1M-151.6M-236.6M-250.5M-276.9M
Net Margin % i-10.6%-38.0%-71.9%-82.0%-106.1%
Key Metrics
EBITDA i38.6M-74.4M-191.9M-196.1M-232.6M
EPS (Basic) i$-0.18$-0.51$-0.82$-0.92$-1.07
EPS (Diluted) i$-0.18$-0.51$-0.82$-0.92$-1.07
Basic Shares Outstanding i304380502295164515289057198271421986258867380
Diluted Shares Outstanding i304380502295164515289057198271421986258867380

Income Statement Trend

Amicus Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i213.8M247.0M148.8M245.2M163.2M
Short-term Investments i36.2M39.2M144.8M237.3M320.0M
Accounts Receivable i101.1M87.6M66.2M52.7M46.9M
Inventory i118.8M59.7M23.8M26.8M19.6M
Other Current Assets34.9M49.5M40.2M34.8M29.7M
Total Current Assets i504.7M483.1M423.8M596.8M579.5M
Non-Current Assets
Property, Plant & Equipment i38.5M42.5M45.9M37.2M38.7M
Goodwill i412.8M416.1M418.6M418.6M418.6M
Intangible Assets i17.2M20.5M23.0M23.0M23.0M
Long-term Investments-----
Other Non-Current Assets13.6M18.6M19.2M24.4M19.1M
Total Non-Current Assets i280.3M294.8M300.4M308.3M307.1M
Total Assets i785.0M777.9M724.2M905.1M886.5M
Liabilities
Current Liabilities
Accounts Payable i12.9M15.1M15.4M21.5M17.1M
Short-term Debt i8.5M8.3M8.6M7.4M6.9M
Current Portion of Long-term Debt-----
Other Current Liabilities8.7M10.4M7.5M4.2M4.1M
Total Current Liabilities i148.7M167.7M139.0M146.0M129.7M
Non-Current Liabilities
Long-term Debt i435.2M436.7M443.6M432.7M434.9M
Deferred Tax Liabilities i--4.9M4.9M4.9M
Other Non-Current Liabilities7.1M13.3M18.5M8.2M6.4M
Total Non-Current Liabilities i442.3M450.0M462.1M451.8M470.5M
Total Liabilities i591.0M617.7M601.1M597.8M600.1M
Equity
Common Stock i2.9M2.9M2.8M2.8M2.6M
Retained Earnings i-2.7B-2.7B-2.5B-2.3B-2.0B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i194.0M160.2M123.0M307.4M286.4M
Key Metrics
Total Debt i443.6M445.1M452.1M440.1M441.7M
Working Capital i356.0M315.4M284.8M450.9M449.8M

Balance Sheet Composition

Amicus Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-56.1M-151.6M-236.6M-250.5M-276.9M
Depreciation & Amortization i8.5M7.9M5.3M6.2M8.8M
Stock-Based Compensation i84.9M86.1M76.5M57.8M49.2M
Working Capital Changes i-112.9M-18.6M-33.7M-12.7M-23.3M
Operating Cash Flow i-73.3M-97.3M-184.7M-200.4M-237.4M
Investing Activities
Capital Expenditures i-----
Acquisitions i-----
Investment Purchases i-114.8M-91.7M-243.3M-341.4M-365.2M
Investment Sales i117.8M197.2M335.9M424.0M354.8M
Investing Cash Flow i3.0M105.5M96.1M82.6M-10.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i0387.4M00385.9M
Debt Repayment i-97.0K-408.3M-283.0K-479.0K-155.3M
Financing Cash Flow i-2.6M51.4M-11.8M182.6M220.6M
Free Cash Flow i-37.4M-76.5M-170.3M-206.4M-236.5M
Net Change in Cash i-72.9M59.6M-100.4M64.9M-27.1M

Cash Flow Trend

Amicus Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -42.28
Forward P/E 47.50
Price to Book 11.46
Price to Sales 4.10
PEG Ratio 47.50

Profitability Ratios

Profit Margin -6.67%
Operating Margin -5.02%
Return on Equity -22.62%
Return on Assets 2.00%

Financial Health

Current Ratio 3.21
Debt to Equity 216.99
Beta 0.53

Per Share Data

EPS (TTM) $-0.12
Book Value per Share $0.66
Revenue per Share $1.86

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
fold2.3B-42.2811.46-22.62%-6.67%216.99
Vertex 101.3B28.085.9022.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
BridgeBio Pharma 9.4B-17.04-5.2636.76%98.25%-1.04
Madrigal 9.1B-18.9413.00-36.30%-54.68%17.81
Halozyme 8.4B16.3925.31179.14%47.28%462.23

Financial data is updated regularly. All figures are in the company's reporting currency.